Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Jagadeesh

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2018
Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell TransplantationSagar S Patel, Lisa A Rybicki, Donna Corrigan, et al.
Leukemia & Lymphoma|August 31, 2017
Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationAllison Winter, Lisa Rybicki, Shetal N Shah, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
Bone Marrow Transplantation|February 11, 2023
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucelAgrima Mian, Wei Wei, Betty K Hamilton, et al.
Bone Marrow Transplantation|September 12, 2023
The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphomaGabriel F P Aleixo, Wei Wei, Po-Hao Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2019
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell TransplantationBrian T Hill, Lisa A Rybicki, Theresa A Urban, et al.
Bone Marrow Transplantation|April 16, 2022
Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplantPranay S Hegde, Lisa Rybicki, Sheila Serafino, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 8, 2022
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoringKelly J Gaffney, Theresa A Urban, Mariana Lucena, et al.
British Journal of Haematology|March 19, 2024
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomasJacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, et al.
British Journal of Haematology|January 21, 2020
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantationHassan Awada, Reda Z Mahfouz, Jibran Durrani, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2018
Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell TransplantationSagar S Patel, Lisa A Rybicki, Donna Corrigan, et al.
Leukemia & Lymphoma|August 31, 2017
Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationAllison Winter, Lisa Rybicki, Shetal N Shah, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
Bone Marrow Transplantation|February 11, 2023
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucelAgrima Mian, Wei Wei, Betty K Hamilton, et al.
Bone Marrow Transplantation|September 12, 2023
The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphomaGabriel F P Aleixo, Wei Wei, Po-Hao Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2019
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell TransplantationBrian T Hill, Lisa A Rybicki, Theresa A Urban, et al.
Bone Marrow Transplantation|April 16, 2022
Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplantPranay S Hegde, Lisa Rybicki, Sheila Serafino, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 8, 2022
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoringKelly J Gaffney, Theresa A Urban, Mariana Lucena, et al.
British Journal of Haematology|March 19, 2024
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomasJacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, et al.
British Journal of Haematology|January 21, 2020
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantationHassan Awada, Reda Z Mahfouz, Jibran Durrani, et al.
Pageof 10